MARKET

RNAC

RNAC

Cartesian
NASDAQ
8.84
-0.01
-0.11%
Opening 09:40 08/10 EDT
OPEN
8.79
PREV CLOSE
8.85
HIGH
8.85
LOW
8.77
VOLUME
7.11K
TURNOVER
--
52 WEEK HIGH
12.57
52 WEEK LOW
5.60
MARKET CAP
267.46M
P/E (TTM)
-1.4988
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at RNAC last week (0803-0807)?
Weekly Report · 18h ago
Cantor Fitzgerald Keeps Their Buy Rating on Cartesian Therapeutics (RNAC)
TipRanks · 3d ago
Cartesian Therapeutics: Late-Stage Descartes-08 De-Risking and 2027 Data Wave Underpin Van Buren’s Buy Rating
TipRanks · 3d ago
Cartesian Therapeutics Announces New Employment Inducement Grants
Barchart · 3d ago
Buy Rating Reiterated on Strong Cash Runway and Near‑Term Clinical Catalysts; $40 Price Target Maintained
TipRanks · 4d ago
Cartesian Therapeutics Q2 EPS $0.46 Beats $(0.86) Estimate
Benzinga · 4d ago
*Cartesian Therapeutics 2Q Research and Development Expenses $20.4M >RNAC
Dow Jones · 4d ago
*Cartesian Therapeutics 2Q EPS 46c >RNAC
Dow Jones · 4d ago
More
About RNAC
Cartesian Therapeutics, Inc. is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. It leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. The Company’s lead asset, Descartes-08, is a chimeric antigen receptor T-cell therapy (CAR-T) entering Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-B-cell maturation antigen (BCMA) CAR-T being evaluated in a Phase 1 trial in patients with multiple myeloma. Descartes-08 is an autologous chimeric antigen receptor T-cell therapy product targeting B-cell maturation antigen in clinical development for generalized myasthenia gravis and systemic lupus erythematosus.

Webull offers Cartesian Therapeutics Inc stock information, including NASDAQ: RNAC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RNAC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RNAC stock methods without spending real money on the virtual paper trading platform.